ARGENX SE - ADR (ARGX) Stock Fundamental Analysis
USA - NASDAQ:ARGX - US04016X1019 - ADR
891.73 USD
+1.84 (+0.21%)
880.18 USD
-11.55 (-1.3%)
ARGX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While ARGX has a great health rating, its profitability is only average at the moment. ARGX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, ARGX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
ARGX had positive earnings in the past year.
In the past year ARGX had a positive cash flow from operations.
In the past 5 years ARGX reported 4 times negative net income.
In the past 5 years ARGX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ARGX (17.84%) is better than 96.42% of its industry peers.
ARGX's Return On Equity of 21.00% is amongst the best of the industry. ARGX outperforms 95.86% of its industry peers.
ARGX has a better Return On Invested Capital (6.01%) than 92.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 6.01% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ARGX (41.97%) is better than 97.74% of its industry peers.
With an excellent Operating Margin value of 15.30%, ARGX belongs to the best of the industry, outperforming 93.41% of the companies in the same industry.
ARGX has a better Gross Margin (89.40%) than 91.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ARGX has more shares outstanding
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
Compared to 1 year ago, ARGX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 31.93 indicates that ARGX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 31.93, ARGX belongs to the best of the industry, outperforming 95.10% of the companies in the same industry.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
ARGX has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. ARGX outperforms 95.86% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
ARGX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ARGX outperforms 45.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 31.93 |
ROIC/WACC0.8
WACC7.52%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.60, ARGX is doing good in the industry, outperforming 60.45% of the companies in the same industry.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX's Quick ratio of 5.27 is in line compared to the rest of the industry. ARGX outperforms 59.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
The Revenue has grown by 64.65% in the past year. This is a very strong growth!
The Revenue has been growing by 94.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.65%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%91.37%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 106.11% on average per year.
The Revenue is expected to grow by 33.99% on average over the next years. This is a very strong growth
EPS Next Y867.29%
EPS Next 2Y297.24%
EPS Next 3Y171.03%
EPS Next 5Y106.11%
Revenue Next Year89.57%
Revenue Next 2Y60.07%
Revenue Next 3Y45.87%
Revenue Next 5Y33.99%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 66.50, which means the current valuation is very expensive for ARGX.
ARGX's Price/Earnings ratio is rather cheap when compared to the industry. ARGX is cheaper than 90.21% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.91. ARGX is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 30.27, ARGX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 91.15% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.57. ARGX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.5 | ||
| Fwd PE | 30.27 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 90.02% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 90.58% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 177.84 | ||
| EV/EBITDA | 100.6 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARGX's earnings are expected to grow with 171.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y297.24%
EPS Next 3Y171.03%
5. Dividend
5.1 Amount
ARGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
891.73
+1.84 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.51%
Inst Owner Change-1.57%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap54.90B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts84.8
Price Target866.57 (-2.82%)
Short Float %3.02%
Short Ratio5.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14.45%
Revenue beat(16)13
Avg Revenue beat(16)17.87%
PT rev (1m)1.55%
PT rev (3m)3.84%
EPS NQ rev (1m)0.72%
EPS NQ rev (3m)5.87%
EPS NY rev (1m)7.49%
EPS NY rev (3m)43.78%
Revenue NQ rev (1m)0.56%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)2.3%
Revenue NY rev (3m)12.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.5 | ||
| Fwd PE | 30.27 | ||
| P/S | 18 | ||
| P/FCF | 177.84 | ||
| P/OCF | 135.98 | ||
| P/B | 9.01 | ||
| P/tB | 9.34 | ||
| EV/EBITDA | 100.6 |
EPS(TTM)13.41
EY1.5%
EPS(NY)29.46
Fwd EY3.3%
FCF(TTM)5.01
FCFY0.56%
OCF(TTM)6.56
OCFY0.74%
SpS49.55
BVpS99.01
TBVpS95.45
PEG (NY)0.08
PEG (5Y)N/A
Graham Number172.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 6.01% | ||
| ROICexc | 16.72% | ||
| ROICexgc | 18.56% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 31.93 |
F-Score5
WACC7.52%
ROIC/WACC0.8
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y867.29%
EPS Next 2Y297.24%
EPS Next 3Y171.03%
EPS Next 5Y106.11%
Revenue 1Y (TTM)64.65%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%91.37%
Revenue Next Year89.57%
Revenue Next 2Y60.07%
Revenue Next 3Y45.87%
Revenue Next 5Y33.99%
EBIT growth 1Y207%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.72%
EBIT Next 3Y205.97%
EBIT Next 5Y121.7%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.79%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE - ADR / ARGX FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.
What is the valuation status of ARGENX SE - ADR (ARGX) stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for ARGX stock?
The Earnings per Share (EPS) of ARGENX SE - ADR (ARGX) is expected to grow by 867.29% in the next year.